Pharmacoeconomic Report: Vedolizumab (Entyvio SC): Takeda Canada Inc [Internet]
- PMID: 33347112
- Bookshelf ID: NBK565523
Pharmacoeconomic Report: Vedolizumab (Entyvio SC): Takeda Canada Inc [Internet]
Excerpt
Given issues with the stability of the sponsor’s probabilistic analysis (i.e., wide variation in the incremental cost-effectiveness ratios [ICERs] at each model run due in part to the wide credible intervals within the sponsor’s submitted network meta-analysis [NMA]), CADTH conducted reanalyses deterministically for both the anti–tumour necrosis factor (TNF) alpha naive populations and anti–TNF alpha exposed populations as distinct populations. CADTH also accounted for limitations by including relevant comparators, revising the probability of surgery and of post-surgery complications, adjusting costs and resource use, and switching off dose escalation and the loss and regaining of response.
In the anti–TNF alpha naive population, subcutaneous (SC) vedolizumab was dominated by tofacitinib (i.e., tofacitinib was associated with more quality-adjusted life-years [QALYs] at a lower cost compared with vedolizumab SC). In the anti–TNF alpha exposed population, vedolizumab SC was found to be the optimal therapy at a willingness to pay (WTP) above $1,152,959 per QALY gained when compared with tofacitinib. Between a WTP threshold of $117,761 to $1,152,959 per QALY gained, tofacitinib would be the optimal therapy, while below a WTP threshold $117,761 per QALY gained, conventional therapy would be the optimal therapy.
Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.
Sections
- Abbreviations
- Executive Summary
- Stakeholder Input Relevant to the Economic Review
- Economic Review
- Appendix 1. Cost Comparison Table
- Appendix 2. Submission Quality
- Appendix 3. Detailed Information on the Submitted Economic Evaluation
- Appendix 4. CADTH Detailed Reanalyses and Sensitivity Analyses of the Economic Evaluation
- References
Similar articles
-
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.Pharmacoecon Open. 2022 Jul;6(4):519-537. doi: 10.1007/s41669-022-00331-9. Epub 2022 Apr 26. Pharmacoecon Open. 2022. PMID: 35474178 Free PMC article.
-
Pharmacoeconomic Report: Eculizumab (Soliris): Alexion Pharma Canada Corporation: Indication: Adult patients with generalized Myasthenia Gravis [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec. PMID: 33570893 Free Books & Documents. Review.
-
Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie): Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Mar. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Mar. PMID: 32598110 Free Books & Documents. Review.
-
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. doi: 10.3310/hta11470. Health Technol Assess. 2007. PMID: 17999842 Review.
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047 Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
